Verdiva Bio
The company develops peptide-based therapies for obesity and cardiometabolic diseases, utilizing a proprietary oral absorption enhancer called T2026. Its lead candidate, VRB-101, is a once-weekly oral GLP-1 receptor agonist currently in Phase 2 clinical trials. The pipeline also includes amylin-based product candidates and combination therapies in both oral and injectable formats.
Visit websiteLondon, UK
Biotechnology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €398.9M
- Funding rounds
- 1
Investors in Verdiva Bio
Investors on record for Verdiva Bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Verdiva Bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors